These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24338553)

  • 1. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway.
    Lu M; Wang H; Wang J; Zhang J; Yang J; Liang L; Maslov LN
    Planta Med; 2014 Jan; 80(1):63-9. PubMed ID: 24338553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
    Zhang S; Tang F; Yang Y; Lu M; Luan A; Zhang J; Yang J; Wang H
    PLoS One; 2015; 10(3):e0118759. PubMed ID: 25738576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
    Dai H; Jia G; Liu X; Liu Z; Wang H
    Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.
    Tan X; Li J; Wang X; Chen N; Cai B; Wang G; Shan H; Dong D; Liu Y; Li X; Yang F; Li X; Zhang P; Li X; Yang B; Lu Y
    Int J Biol Sci; 2011 Apr; 7(3):383-9. PubMed ID: 21494433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells.
    Liu CJ; Cheng YC; Lee KW; Hsu HH; Chu CH; Tsai FJ; Tsai CH; Chu CY; Liu JY; Kuo WW; Huang CY
    Mol Cell Biochem; 2008 Jun; 313(1-2):167-78. PubMed ID: 18398669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy.
    Yang J; Wang HX; Zhang YJ; Yang YH; Lu ML; Zhang J; Li ST; Zhang SP; Li G
    J Ethnopharmacol; 2013 Dec; 150(3):1062-70. PubMed ID: 24432369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
    Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
    Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein.
    Huang H; Lai S; Wan Q; Qi W; Liu J
    Can J Physiol Pharmacol; 2016 May; 94(5):542-53. PubMed ID: 27070866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betulinic Acid Protects DOX-Triggered Cardiomyocyte Hypertrophy Response through the GATA-4/Calcineurin/NFAT Pathway.
    Yoon JJ; Son CO; Kim HY; Han BH; Lee YJ; Lee HS; Kang DG
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway.
    Li X; Lan Y; Wang Y; Nie M; Lu Y; Zhao E
    Mol Med Rep; 2017 May; 15(5):2574-2582. PubMed ID: 28447738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astragaloside IV protects against the pathological cardiac hypertrophy in mice.
    Liu ZH; Liu HB; Wang J
    Biomed Pharmacother; 2018 Jan; 97():1468-1478. PubMed ID: 29793309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase.
    Xu XL; Chen XJ; Ji H; Li P; Bian YY; Yang D; Xu JD; Bian ZP; Zhang JN
    Pharmacology; 2008; 81(4):325-32. PubMed ID: 18349554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
    Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
    Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
    Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
    Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.
    Asadi F; Razmi A; Dehpour AR; Shafiei M
    J Pharm Pharmacol; 2016 Apr; 68(4):485-93. PubMed ID: 26945895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.
    Lu Q; Yi X; Cheng X; Sun X; Yang X
    In Vitro Cell Dev Biol Anim; 2015 Apr; 51(4):353-60. PubMed ID: 25475041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers.
    Horiba M; Muto T; Ueda N; Opthof T; Miwa K; Hojo M; Lee JK; Kamiya K; Kodama I; Yasui K
    Life Sci; 2008 Mar; 82(11-12):554-60. PubMed ID: 18275974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
    Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q
    Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.